Sertraline Treatment for Pediatric Major Depressive Disorder
This paper presents a clinical case study of an 8-year-old African American male diagnosed with major depressive disorder (MDD) and traces three sequential prescribing decisions made by a psychiatric nurse practitioner. Beginning with Sertraline 25 mg, the treatment plan is escalated to 50 mg after an inadequate initial response, then maintained at that dose following a 50% reduction in depressive symptoms. At each decision point, the paper explains why alternative medications — including Paxil, Wellbutrin, Prozac, and SNRIs — were rejected due to pediatric safety concerns and suicidality risk. Ethical constraints governing pediatric dosing, informed consent, and family communication are discussed throughout. The paper concludes by recommending psychotherapy as a complement to pharmacotherapy.
- Introduction: Mood Disorders in Children: Prevalence and background of pediatric mood disorders
- Patient Case Scenario: 8-year-old male patient presenting with depression
- Decision 1: Initiating Sertraline 25 mg: Rationale for starting low-dose Sertraline
- Decision 2: Increasing Sertraline to 50 mg: Dose escalation after inadequate initial response
- Decision 3: Maintaining Sertraline at 50 mg: Continuing effective dose and adding psychotherapy
- Conclusion: Summary of treatment decisions and recommendations
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Each decision point is organized with a clear, consistent structure — what was chosen, why it was chosen, why alternatives were rejected, the intended outcome, and the ethical implications — making the clinical reasoning easy to follow.
- The paper grounds each pharmacological choice in specific drug mechanisms (e.g., serotonin reuptake inhibition, CYP450 metabolism) and cites pediatric safety data, demonstrating applied psychopharmacology knowledge.
- Ethical considerations are woven into every decision rather than treated as an afterthought, showing how practitioner ethics directly shape treatment sequencing and family communication in pediatric care.
Key academic technique demonstrated
The paper demonstrates comparative elimination reasoning: rather than simply defending the chosen drug, it systematically rules out each alternative using evidence-based contraindications specific to the patient's profile (suicidality risk, age restrictions, FDA approval status). This technique is a hallmark of clinical decision-writing in graduate-level psychiatric nursing.
Structure breakdown
The paper opens with an epidemiological introduction to pediatric mood disorders, then presents a brief patient vignette establishing the clinical baseline. The core body follows a three-part decision framework, each section mirroring the same analytical template. A short conclusion synthesizes the prescribing rationale and introduces psychotherapy as a complementary next step. References are formatted in APA style.
Introduction: Mood Disorders in Children
According to psychiatrists in the Department of Psychiatry and Behavioural Sciences, the prevalence of mood disorders in the United States is far higher than one might imagine. Irrespective of socioeconomic status, approximately 21.3% of children experience a mood disorder. According to the National Alliance on Mental Illness, the most common mood disorders are bipolar disorder and depression (Gordon et al., 2014). When a mood disorder is not detected and treated, a child can be at risk of developing conditions such as substance use disorder and disruptive behavior.
Adolescents and children suffering from mood disorders do not express the same symptoms as adults; therefore, parents may fail to detect the problem in their children. Treatment of mood disorders varies based on the particular signs and symptoms of depression. Proper treatment requires a full assessment of mental health history, and pharmacological interventions should form part of the treatment plan.
Patient Case Scenario
An 8-year-old African American male patient presented to the hospital with signs of depression. He reported feelings of sadness and regular irritability, as well as a lack of appetite, and his mother noted that he had withdrawn from his classmates. After assessment, his overall mood was established to be sad; however, the child demonstrated clear speech and was alert and oriented. He denied auditory or visual hallucinations, and no paranoid or delusional thought process was identified. Insight and judgment appeared consistent with his age.
The patient acknowledged that he sometimes imagines himself dead and contemplates what that would mean, but he denied active suicidal ideation. The PMHNP recorded a depression rating score of 30 — an indication of substantial depression.
Decision 1: Initiating Sertraline 25 mg
Decision selected: Sertraline 25 mg by mouth daily.
Sertraline (Zoloft) 25 mg was selected as the initial dosage. The drug is administered at a lower dose because antidepressants used for the first time tend to increase anxiety (Stahl, 2014). Sertraline treats severe panic disorder, obsessive-compulsive disorder, depressive disorder, premenstrual dysphoric disorder, posttraumatic stress disorder, and social anxiety disorder. It can be administered alone or alongside other medications and belongs to the antidepressant class of drugs (Gordon et al., 2014). Studies show that Sertraline has demonstrated a response rate of 50–70% in treating depression in children. Furthermore, Sertraline enhances mood primarily by restoring serotonin balance in the brain.
Alternatives not selected: Paxil 10 mg by mouth daily and Wellbutrin 75 mg by mouth twice daily.
Paxil is a commonly prescribed drug for treating depression in children. It is a potent 5-HT receptor inhibitor and is also slightly metabolized by cytochrome P450 (2D6) (Stahl, 2021). It has been used successfully for panic disorder, generalized anxiety disorder, social phobia, obsessive-compulsive disorder, and depression (Stahl, 2014). However, studies have found the drug to carry an inherent risk of suicide, and patients taking it should be screened for suicide attempts (Lorberg et al., 2019). Given the current clinical status of this patient, Paxil was considered unsafe.
Wellbutrin, on the other hand, may result in behavioral changes such as depressed mood, suicidal thoughts, agitation, or hostility. These side effects — particularly suicidal thoughts — are significantly more pronounced in children (Stahl, 2014). Because the patient had already shown signs consistent with passive suicidal ideation, Wellbutrin was contraindicated.
Intended outcome: Sertraline was intended to induce serotonin balance in the brain, thereby addressing the depression by enhancing the patient's mood (Stahl, 2021). Nevertheless, the patient returned to the hospital one month later with no significant change in depressive symptoms.
Ethical considerations: Ethical constraints sometimes limit clinical discretion in administering treatment plans. Even though the patient recorded a high depression score of 30, the first dose of Sertraline had to remain low to comply with ethical standards. However, this low dosage was likely insufficient to produce significant positive change.
Conclusion
Children can sometimes express irritability as part of their normal developmental process. However, parents should carefully monitor critical warning signs such as isolation from peers or classmates, complaints of feeling hated or rejected by other children, and persistent withdrawal. Such signs are, in most cases, early indicators of anxiety (Gordon et al., 2014). Caregivers, teachers, and parents should therefore be familiar with what typical adolescent behavior looks like in order to identify and address potential health concerns early.
In this case, Sertraline (Zoloft) 25 mg was administered as the initial dose, kept low because antidepressants introduced for the first time tend to increase anxiety. Escalating to 50 mg daily was clinically appropriate, as it represents the standard therapeutic dose for children and produced a meaningful reduction in symptoms. Ultimately, maintaining Sertraline at 50 mg was ethically sound given the patient's positive response to that dose. Introducing psychotherapy as a complementary intervention represents the recommended next step toward full remission.
References
Gordon, M. S., & Melvin, G. A. (2014). Do antidepressants make children and adolescents suicidal? Journal of Paediatrics and Child Health, 50(11), 847–854.
Lorberg, B., Davico, C., Martsenkovskyi, D., & Vitiello, B. (2019). Principles in using psychotropic medication in children and adolescents. In IACAPAP e-Textbook of Child and Adolescent Mental Health (pp. A7). International Association for Child and Adolescent Psychiatry and Allied Professions.
Simon, A. E., Pastor, P. N., Reuben, C. A., Huang, L. N., & Goldstrom, I. D. (2015). Use of mental health services by children ages six to 11 with emotional or behavioral difficulties. Psychiatric Services, 66(9), 930–937.
Stahl, S. M. (2014). Stahl's essential psychopharmacology prescriber's guide. Cambridge University Press.
Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press.
Always verify citation format against your institution’s current style guide requirements.